In the present study, we observed that administration of the CXCR2 antagonist SB225002 reduced peritoneal metastasis along the incisional wound by 70%, indicating that CXCR2 expressed on colon cancer cells plays an important role in the development of peritoneal surface metastases. Here, CXCR2 is linked to malignant colon neoplasm.